3. Anthim


Active ingredient: obiltoxaximab
Disease: inhalational anthrax
Peak sales estimate: n/a
Approved: March 18
Company: Elusys Therapeutics

The scoop: After receiving years of federal support to the tune of more than $240 million, Elusys won approval in May for its Anthim to treat inhalational anthrax, caused by exposure to contaminated animals or by an intentional release of bacteria spores. Based out of Pine Brook, NJ, Elusys worked with a unit of the Department of Health and Human Services to develop Anthim, which now represents a new tool for bioterrorism preparedness. Other funders for the biotech include venture groups from Pfizer and AstraZeneca’s MedImmune. Anthim was approved under the FDA’s animal rule, which allows the agency to consider animal data when human studies aren’t an option. Its safety was studied in 320 humans, however. -- Eric Sagonowsky

3. Anthim

Suggested Articles

In this week's EuroBiotech Report, AstraZeneca plans 2020 lupus filing, Roche's SMA trial hits endpoint and Kiadis cuts staff in R&D pivot.

In our EuroBiotech roundup this week, NEC and Vaximm ink cancer vaccine pact, Compugen posts cancer data and Lunac raises cash.

Biotech venture fund ATAI Life Sciences has partnered with artificial intelligence drug discovery specialist Cyclica to form a new JV.